BRIEF—New Zealand to fund Prolia

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced a decision to fund Prolia (denosumab), from US biotech major Amgen, for the treatment of severe, established osteoporosis, subject to certain clinical criteria being met.

Denosumab (Prolia) will be listed in Section B and in Part II of Section H of the Pharmaceutical Schedule from July 1, 2018, at the following price and subsidy (ex-manufacturer, excluding GST) of NZ$326.00 ($230) per 60mg prefilled syringe.

A confidential rebate will apply to Prolia that will reduce its net price to the Funder.

Prolia will be listed in Section B of the Pharmaceutical Schedule subject to the Special Authority criteria.